leisure time -WSS

leisure time

author：leisure time 2025-09-28 19:25:17 - browse：88

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： With trial win, GSK could get blood cancer drug back on market

focus

WSS

Let's speed up science by embracing open access publishing

BioAge raises $170M for combination therapy with Zepbound

How digital tools helped lower hypertension in marginalized patients

Medicare Advantage proposed rates disappoint insurers

How digital tools helped lower hypertension in marginalized patients

For Medicare Advantage, Democrats want stronger protections around AI

Wikipedia

leisure time

Wikipedia

Peter Hotez and the public health issue of online harassment

Key House Republican on health care plans exit from Congress

Anesthesiologist group: stop taking Ozempic before surgery

Ionis drug prevents swelling attacks due to hereditary angioedema

State Dept. review finds Biden bears some blame for Afghanistan failures

Gilead might be held responsible for not developing a drug

Wildfire smoke exposes gaps in outdoor worker protections

With trial win, GSK could get blood cancer drug back on market

Walensky prepares to leave CDC — and Congress — behind

How to increase colonoscopy rates? Looks like an AI can help

Wikipedia

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Robert F. Kennedy is pitching centrism on health, even on abortion

NIH documents show early flaws of $1.6 billion long Covid program

BioAge raises $170M for combination therapy with Zepbound

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Medical mystery: When a cough is not just a cough

knowledge

focus

knowledge

Wikipedia